Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 3, 2009, Pages 311-318

  Skottheim, I B ^a   Stormark, K ^b   Christensen, H ^a   Jakobsen, G S ^b   Hjelmesaeth J ^b   Jenssen, T ^a,c   Reubsaet, J L E ^a   Sandbu, R ^b   Asberg A ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b VESTFOLD HOSPITAL TRUST   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; ESOMEPRAZOLE; LANSOPRAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EXPOSURE; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; METABOLIC CAPACITY; MORBID OBESITY; MORNING DOSAGE; PRIORITY JOURNAL; STOMACH BYPASS; TREATMENT WITHDRAWAL;

ACIDS; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 CYP3A; DNA; FEMALE; GASTRIC BYPASS; GENOTYPE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LACTONES; MALE; MIDDLE AGED; OBESITY, MORBID; P-GLYCOPROTEIN; PROSPECTIVE STUDIES; PYRROLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 69449099498     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.82     Document Type: Article

References (37)

1. Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement. Am. J. Clin. Nutr. 55 (2 suppl.),615S-619S (1992).
2. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation on Obesity, Geneva, Switzerland, 3-5 June 1997. WHO/NUT/NCD/98.1.
3. Santry, H.P., Gillen, D.L. & Lauderdale, D.S. Trends in bariatric surgical procedures. JAMA 294, 1909-1917 (2005).
4. Sjöström, L. et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med. 351, 2683-2693 (2004). (Pubitemid 39665322)
5. Tichansky, D. & DeMaria, E. Laparoscopic Roux-en-Y gastric bypass: linear stapled technique. In Laparoscopic Bariatric Surgery (eds. DeMaria, E.J. & Ikramuddin, S.) 102-106 (Lippincott Williams & Williams, Philadelphia, PA, 2005). (Pubitemid 41565137)
6. Buchwald, H. & Buchwald, J.N. Evolution of operative procedures for the management of morbid obesity 1950-2000. Obes. Surg. 12, 705-717 (2002).
7. Kelley, M. et al. Change in oral absorption of tacrolimus in a liver transplant recipient after reversal of jejunoileal bypass: case report. Transplant. Proc. 37, 3165-3167 (2005). (Pubitemid 41435651)
8. Rogers, C.C., Alloway, R.R., Alexander, J.W., Cardi, M., Trofe, J. & Vinks, A.A. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. Clin. Transplant. 22, 281-291 (2008). (Pubitemid 351689658)
9. Marterre, W.F., Hariharan, S., First, M.R. & Alexander, J.W. Gastric bypass in morbidly obese kidney transplant recipients. Clin. Transplant. 10, 414-419 (1996). (Pubitemid 26363119)
10. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. & Guengerich, F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414-423 (1994). (Pubitemid 24229655)
11. Paine, M.F. et al. First-pass metabolism of midazolam by the human intestine. Clin. Pharmacol. Ther. 60, 14-24 (1996).
12. de Wildt, S.N., Kearns, G.L., Leeder, J.S. & van den Anker, J.N. Cytochrome P450 3A: ontogeny and drug disposition. Clin. Pharmacokinet. 37, 485-505 (1999).
13. Beringer, P.M. & Slaughter, R.L. Transporters and their impact on drug disposition. Ann. Pharmacother. 39, 1097-1108 (2005).
14. Mealey, K.L. Therapeutic implications of the MDR-1 gene. J. Vet. Pharmacol. Ther. 27, 257-264 (2004).
15. Fenner, K.S. et al. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin. Pharmacol. Ther. 85, 173-181 (2008).
16. Lown, K.S. et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Invest. 99, 2545-2553 (1997).
17. Englund, G. et al. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur. J. Pharm. Sci. 29, 269-277 (2006). (Pubitemid 44602404)
18. Thörn, M., Finnström, N., Lundgren, S., Rane, A. & Lööf, L. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br. J. Clin. Pharmacol. 60, 54-60 (2005). (Pubitemid 40942781)
19. Williams, D. & Feely, J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin. Pharmacokinet. 41, 343-370 (2002). (Pubitemid 34713089)
20. Schachter, M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam. Clin. Pharmacol. 19, 117-125 (2005).
21. Prueksaritanont, T., Ma, B., Fang, X., Subramanian, R., Yu, J. & Lin, J.H. Betaoxidation of simvastatin in mouse liver preparations. Drug Metab. Dispos. 29, 1251-1255 (2001). (Pubitemid 32896572)
22. Prueksaritanont, T. et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab. Dispos. 30, 505-512 (2002). (Pubitemid 34456970)
23. Kearney, A.S., Crawford, L.F., Mehta, S.C. & Radebaugh, G.W. The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981. Pharm. Res. 10, 1461-1465 (1993).
24. Canaparo, R. et al. Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum. Clin. Exp. Pharmacol. Physiol. 34, 1138-1144 (2007). (Pubitemid 47416351)
25. Lindell, M., Karlsson, M.O., Lennernäs, H., Påhlman, L. & Lang, M.A. Variable expression of CYP and Pgp genes in the human small intestine. Eur. J. Clin. Invest. 33, 493-499 (2003). (Pubitemid 36754214)
26. von Richter, O., Burk, O., Fromm, M.F., Thon, K.P., Eichelbaum, M. & Kivisto, K.T. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin. Pharmacol. Ther. 75, 172-183 (2004). (Pubitemid 38314866)
27. Tubic-Grozdanis, M. et al. Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms. Pharm. Res. 25, 1591-1600 (2008).
28. Ando, H. et al. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br. J. Clin. Pharmacol. 60, 494-497 (2005). (Pubitemid 41532449)
29. Lilja, J.J., Kivistö, K.T. & Neuvonen, P.J. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin. Pharmacol. Ther. 66, 118-127 (1999).
30. Wrighton, S. et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol. 38, 207-213 (1990). (Pubitemid 20255306)
31. Kuehl, P. et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391 (2001). (Pubitemid 32268418)
32. Hoffmeyer, S. et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97, 3473-3478 (2000). (Pubitemid 30183327)
33. Hermann, M., Christensen, H. & Reubsaet, J.L. Determination of atorvastatin and metabolites in human plasma with solid-phase extraction followed by LC-tandem MS. Anal. Bioanal. Chem. 382, 1242-1249 (2005). (Pubitemid 40983114)
34. Siegmund, W. et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin. Pharmacol. Ther. 72, 572-583 (2002). (Pubitemid 36237729)
35. Katz, D.A. et al. CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels. Clin. Pharmacol. Ther. 75, 516-528 (2004).
36. Lemahieu, W.P. et al. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am. J. Transplant. 5, 2236-2243 (2005).
37. Committee for Proprietary Medicinal Products (2001). Note for guidance on the investigation of bioavailability and bioequivalence, London, 26 July 2001. CHMP/EWP/QWP/1401/98.